| Company: | Gilead Sciences, Inc. |
| Ticker Symbol: | NASD: GILD |
| Class Period: | July 14, 2003 to October 28, 2003 |
| Court: | Northern District, CA |
| Date Filed: | Nov-17-03 |
| Lead Plaintiff Deadline: | Jan-12-04 |
| Allegations: |
A class action lawsuit has been filed in the United States District Court for the Northern District of California, civil action number C-03-4999, on behalf of all persons or entities who purchased or otherwise acquired Gilead Sciences, Inc. ("Gilead" or the "Company") securities (Nasdaq:GILD) during the class
period: July 14, 2003 and October 28, 2003, inclusive. The Complaint names Gilead Sciences, Inc., John C. Martin, John F. Milligan, Mark L. Perry, Norbert W. Bischofberger, Anthony Carraciolo, and William A. Lee as defendants.
The Complaint alleges that Gilead and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the SEC. The Complaint further alleges that, in a scheme to allow Gilead insiders to sell their Gilead stock at artificially inflated prices, the defendants falsely represented that the strength of its sales of Viread (Gilead's HIV drug), during the second quarter of 2003. Defendants maintained that the strong sales numbers were due to an increase in prescriptions and not, as some analysts had cautioned, due to inventory build-up by distributors stocking up ahead of a price increase.
Such statements were materially false and misleading because, as defendants knew or recklessly disregarded, a material portion of the second quarter Viread sales were attributable to distributors stocking up ahead of a price increase. Gilead insiders sold a total of 303,981 shares in August 2003, reaping gross proceeds of $19,365,998, due to the artificially inflated prices. Gilead announced on October 28, 2003 that sales of Viread in the third quarter of 2003 would be materially less than expected because distributors would meet end-user demand for Viread by selling off overstock they accumulated in the second quarter. After the announcement and in reaction to it, the price of Gilead common stock plummeted, falling $7.46 in one day, from a close of $59.46 per share on October 28, 2003 to $52 per share on October 29, 2003.
If you acquired the securities of the defendants during the Class Period you may, no later than Jan-12-04, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
The Complaint alleges that Gilead and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the SEC. The Complaint further alleges that, in a scheme to allow Gilead insiders to sell their Gilead stock at artificially inflated prices, the defendants falsely represented that the strength of its sales of Viread (Gilead's HIV drug), during the second quarter of 2003. Defendants maintained that the strong sales numbers were due to an increase in prescriptions and not, as some analysts had cautioned, due to inventory build-up by distributors stocking up ahead of a price increase.
Such statements were materially false and misleading because, as defendants knew or recklessly disregarded, a material portion of the second quarter Viread sales were attributable to distributors stocking up ahead of a price increase. Gilead insiders sold a total of 303,981 shares in August 2003, reaping gross proceeds of $19,365,998, due to the artificially inflated prices. Gilead announced on October 28, 2003 that sales of Viread in the third quarter of 2003 would be materially less than expected because distributors would meet end-user demand for Viread by selling off overstock they accumulated in the second quarter. After the announcement and in reaction to it, the price of Gilead common stock plummeted, falling $7.46 in one day, from a close of $59.46 per share on October 28, 2003 to $52 per share on October 29, 2003.
If you acquired the securities of the defendants during the Class Period you may, no later than Jan-12-04, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
If you feel you qualify for damages or remedies that might be awarded in this class action please fill in our form on the right to submit your complaint.
If your injustice does not match the complaint described above, please use this form to register your complaint. Thank you.
